TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF OBESITY
4.2.2 INCREASING GOVERNMENT INITIATIVES AND SUPPORT
4.3 RESTRAINTS
4.3.1 SIDE EFFECTS AND SAFETY CONCERNS
4.4 OPPORTUNITY
4.4.1 FOCUS ON NON-SURGICAL OBESITY TREATMENTS
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET
5.3 MARKET TRENDS
5.4 REGULATORY LANDSCAPE
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA-PACIFIC
5.4.4 LATIN AMERICA
5.4.5 MIDDLE EAST AND AFRICA
5.5 UNMET NEEDS
5.6 EPIDEMIOLOGY ASSESSMENT
5.7 BRAND AND PIPELINE ANALYSIS
5.8 PRICING ANALYSIS
6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE
6.1 OVERVIEW
6.1 APPETITE SUPPRESSANTS
6.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
6.1.2 SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS
6.1.3 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)
6.2 LIPASE INHIBITORS
6.3 GLP-1 RECEPTOR AGONISTS
6.4 COMBINATION DRUGS
6.5 OTHERS
7 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 PRESCRIPTION DRUGS
7.3 OVER THE COUNTER DRUGS
8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION
8.1 OVERVIEW
8.2 CENTRALLY ACTING ANTI-OBESITY DRUGS
8.3 PERIPHERALLY ACTING ANTI-OBESITY DRUGS
9 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 SUBCUTANEOUS
10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACIES
10.3 RETAIL PHARMACIES
10.4 ONLINE PHARMACIES
11 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 SPAIN
11.3.5 ITALY
11.3.6 RUSSIA
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.2 INDIA
11.4.3 JAPAN
11.4.4 SOUTH KOREA
11.4.5 MALAYSIA
11.4.6 THAILAND
11.4.7 INDONESIA
11.4.8 REST OF ASIA PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 MEXICO
11.5.3 ARGENTINA
11.5.4 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 GCC COUNTRIES
11.6.2 SOUTH AFRICA
11.6.3 REST OF MEA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS, 2024
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.1.1 PRODUCT APPROVAL
12.1.2 MARKETING APPROVAL
12.1.3 PRODUCT EXPANSION
12.1.4 FACILITY LAUNCH
12.1.5 AQUISITION
12.1.6 AGREEMENT
13 COMPANY PROFILES
13.1 ELI LILLY AND COMPANY
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ASTRAZENECA
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 GSK PLC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCT OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 GELESIS
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 CHEPLAPHARM ARZNEIMITTEL GMBH
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCT OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 KEY STRATEGIES
13.6 NOVO NORDISK A/S
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 RHYTHM PHARMACEUTICALS, INC.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 KVK TECH, INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 KEY STRATEGIES
13.9 CURRAX PHARMACEUTICALS LLC
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 KEY STRATEGIES
13.10 VIVUS LLC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 KEY STRATEGIES
14 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 BRAND AND PIPELINE ANALYSIS
TABLE 3 PRICING ANALYSIS
TABLE 4 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 5 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY REGION, 2019–2035 (USD BILLION)
TABLE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 7 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2019–2035 (USD BILLION)
TABLE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS, BY REGION, 2019–2035 (USD BILLION)
TABLE 9 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS), BY REGION, 2019–2035 (USD BILLION)
TABLE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR LIPASE INHIBITORS, BY REGION, 2019–2035 (USD BILLION)
TABLE 11 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR GLP-1 RECEPTOR AGONISTS, BY REGION, 2019–2035 (USD BILLION)
TABLE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR COMBINATION DRUGS, BY REGION, 2019–2035 (USD BILLION)
TABLE 13 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 15 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2019–2035 (USD BILLION)
TABLE 16 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OVER-THE-COUNTER DRUGS, BY REGION, 2019–2035 (USD BILLION)
TABLE 17 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 18 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019–2035 (USD BILLION)
TABLE 19 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019–2035 (USD BILLION)
TABLE 20 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 21 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ORAL, BY REGION, 2019–2035 (USD BILLION)
TABLE 22 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SUBCUTANEOUS, BY REGION, 2019–2035 (USD BILLION)
TABLE 23 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 24 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 25 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 26 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 27 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION)
TABLE 28 NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 29 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 30 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 31 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 32 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 33 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 34 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 35 US: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 36 US: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 37 US: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 38 US: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 39 US: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 40 US: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 41 CANADA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 42 CANADA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 43 CANADA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 44 CANADA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 45 CANADA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 46 CANADA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 47 EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 48 EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 49 EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 50 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 51 EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 52 EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 53 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 54 GERMANY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 55 GERMANY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 56 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 57 GERMANY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 58 GERMANY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 59 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 60 FRANCE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 61 FRANCE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 62 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 63 FRANCE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 64 FRANCE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 65 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 66 UK: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 67 UK: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 68 UK: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 69 UK: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 70 UK: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 71 UK: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 72 SPAIN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 73 SPAIN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 74 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 75 SPAIN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 76 SPAIN: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 77 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 78 ITALY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 79 ITALY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 80 ITALY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 81 ITALY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 82 ITALY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 83 ITALY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 84 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 85 RUSSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 86 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 87 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 88 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 89 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 90 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 91 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 92 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 93 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 94 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 95 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 96 ASIA PACIFIC ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION)
TABLE 97 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 98 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 99 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 100 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 101 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 102 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 103 CHINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 104 CHINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 105 CHINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 106 CHINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 107 CHINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 108 CHINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 109 INDIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 110 INDIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 111 INDIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 112 INDIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 113 INDIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 114 INDIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 115 JAPAN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 116 JAPAN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 117 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 118 JAPAN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 119 JAPAN: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 120 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 121 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 122 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 123 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 124 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 125 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 126 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 127 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 128 MALAYSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 129 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 130 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 131 MALAYSIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 132 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 133 THAILAND: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 134 THAILAND: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 135 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 136 THAILAND: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 137 THAILAND: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 138 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 139 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 140 INDONESIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 141 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 142 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 143 INDONESIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 144 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 145 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 146 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 147 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 148 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 149 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 150 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 151 SOUTH AMERICA ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION)
TABLE 152 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 153 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 154 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 155 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 156 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 157 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 158 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 159 BRAZIL: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 160 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 161 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 162 BRAZIL: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 163 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 164 MEXICO: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 165 MEXICO: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 166 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 167 MEXICO: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 168 MEXICO: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 169 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 170 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 171 ARGENTINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 172 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 173 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 174 ARGENTINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 175 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 176 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 177 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 178 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 179 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 180 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 181 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 182 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 183 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 184 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 185 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 186 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 187 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 188 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 189 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 190 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 191 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 192 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 193 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 194 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 195 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 196 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 197 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 198 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 199 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 200 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 201 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)
TABLE 202 REST OF MEA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)
TABLE 203 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)
TABLE 204 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)
TABLE 205 REST OF MEA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 206 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 207 PRODUCT APPROVAL
TABLE 208 MARKETING APPROVAL
TABLE 209 PRODUCT EXPANSION
TABLE 210 FACILITY LAUNCH
TABLE 211 AQUISITION
TABLE 212 AGREEMENT
TABLE 213 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 214 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
TABLE 215 ASTRAZENECA: PRODUCT OFFERED
TABLE 216 ASTRAZENECA: KEY DEVELOPMENTS
TABLE 217 GSK PLC: PRODUCTS OFFERED
TABLE 218 GELESIS: PRODUCT OFFERED
TABLE 219 CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCTS OFFERED
TABLE 220 NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 221 NOVO NORDISK A/S: KEY DEVELOPMENTS
TABLE 222 RHYTHM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 223 RHYTHM PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 224 KVK TECH, INC.: PRODUCTS OFFERED
TABLE 225 CURRAX PHARMACEUTICALS LLC: PRODUCTS OFFERED
TABLE 226 CURRAX PHARMACEUTICALS LLC: KEY DEVELOPMENTS
TABLE 227 VIVUS LLC: PRODUCTS OFFERED
TABLE 228 VIVUS LLC: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL ANTI-OBESITY DRUGS MARKET: STRUCTURE
FIGURE 2 GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) SOURCE: MRR ANALYSIS
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ANTI-OBESITY DRUGS MARKET
FIGURE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2024 & 2035 (USD BILLION)
FIGURE 7 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY TREATMENT TYPE, 2024
FIGURE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2024 & 2035 (USD BILLION)
FIGURE 9 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DRUG TYPE, 2024
FIGURE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2024 & 2035 (USD BILLION)
FIGURE 11 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY MECHANISM OF ACTION, 2024
FIGURE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)
FIGURE 13 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024
FIGURE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)
FIGURE 15 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
FIGURE 16 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD BILLION)
FIGURE 17 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 (%)
FIGURE 18 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 19 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 20 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 21 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 22 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 23 ASIA PACIFIC: MULTIPLE SCLEROSIS TREATMENT DEVICES TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 24 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 25 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 26 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 27 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 28 GLOBAL ANTI-OBESITY DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 29 COMPETITOR DASHBOARD: GLOBAL ANTI-OBESITY DRUGS MARKET
FIGURE 30 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 32 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 ASTRAZENECA: SWOT ANALYSIS
FIGURE 34 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 GSK PLC: SWOT ANALYSIS
FIGURE 36 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 NOVO NORDISK A/S: SWOT ANALYSIS
FIGURE 38 RHYTHM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 RHYTHM PHARMACEUTICALS, INC.: SWOT ANALYSIS
